Samsung Biologics Announces Public Tender Offer for PolyPeptide Group
In a strategic move signaling its aggressive expansion in the biotechnology sector, Samsung Biologics, a prominent contract development and manufacturing organization (CDMO), has announced its intention to acquire PolyPeptide Group AG through a public tender offer. This announcement was made on August 31, 2026, when the company published a detailed prospectus outlining the terms of the offer.
The offer is to purchase all publicly held registered shares of PolyPeptide for approximately CHF 44.31 each, reflecting a total equity value around CHF 1.46 billion. This bid represents a substantial 40% premium over the share price observed prior to the initial media speculations regarding the potential acquisition and an 11.6% premium against the weighted average share price in the preceding 60 trading days.
One of the most compelling endorsements for this action comes from PolyPeptide's Board of Directors, which has unanimously expressed its support for the offer. This validation is reinforced by a fairness opinion provided by the independent financial advisory firm IFBC AG, which conducted a thorough analysis of the proposal's terms. Moreover, Draupnir Holding B.V., the largest shareholder of PolyPeptide holding 55.65% of its shares, has committed to tendering all its shares in line with the offer, showcasing strong backing for the acquisition.
The main offer period is expected to run from September 15 to October 12, 2026. However, the effectiveness of the offer hinges on meeting a minimum acceptance threshold of 66⅔%, along with the necessary regulatory approvals. This stipulation is standard practice in such acquisitions, ensuring a clear pathway for completion once the required support is garnered.
Should this acquisition materialize, Samsung Peptide AG, the Swiss subsidiary acting as the formal offeror, plans to push for a squeeze-out of any remaining minority shareholders. This would mean delisting PolyPeptide's shares from the SIX Swiss Exchange, consolidating ownership more firmly within Samsung Biologics.
Samsung Biologics, based in Incheon, South Korea, boasts a comprehensive biomanufacturing capacity of 845,000 liters across its facilities in Korea and the U.S. This acquisition aims to leverage PolyPeptide's expertise in peptide-based active pharmaceutical ingredients, expanding Samsung Biologics' capabilities in a rapidly growing market. The company continues to innovate and invest in new manufacturing technologies through its ExellenS™ framework, which ensures standardized processes and speedy production.
Furthermore, the market for peptide-based pharmaceuticals is anticipated to evolve significantly, particularly in the therapeutic landscape addressing metabolic diseases. PolyPeptide has been instrumental in this field, establishing itself with a global network of GMP-certified facilities, enhancing its appeal to Samsung Biologics as a robust addition to their growing portfolio.
As both companies look forward to what could be a transformative merger, the attention of the investment community will now focus on the unfolding events during the tender offer period. With the backing of large shareholders and the support of Polypeptide’s Board, Samsung Biologics is poised to redefine its position in the biotechnology industry.
For further information, the detailed offer documentation is accessible on the Samsung Biologics website, providing transparency and clarity regarding the acquisition process. Investors and interested stakeholders are encouraged to review this material closely to understand the implications of this significant strategic development fully.
The offer is to purchase all publicly held registered shares of PolyPeptide for approximately CHF 44.31 each, reflecting a total equity value around CHF 1.46 billion. This bid represents a substantial 40% premium over the share price observed prior to the initial media speculations regarding the potential acquisition and an 11.6% premium against the weighted average share price in the preceding 60 trading days.
One of the most compelling endorsements for this action comes from PolyPeptide's Board of Directors, which has unanimously expressed its support for the offer. This validation is reinforced by a fairness opinion provided by the independent financial advisory firm IFBC AG, which conducted a thorough analysis of the proposal's terms. Moreover, Draupnir Holding B.V., the largest shareholder of PolyPeptide holding 55.65% of its shares, has committed to tendering all its shares in line with the offer, showcasing strong backing for the acquisition.
The main offer period is expected to run from September 15 to October 12, 2026. However, the effectiveness of the offer hinges on meeting a minimum acceptance threshold of 66⅔%, along with the necessary regulatory approvals. This stipulation is standard practice in such acquisitions, ensuring a clear pathway for completion once the required support is garnered.
Should this acquisition materialize, Samsung Peptide AG, the Swiss subsidiary acting as the formal offeror, plans to push for a squeeze-out of any remaining minority shareholders. This would mean delisting PolyPeptide's shares from the SIX Swiss Exchange, consolidating ownership more firmly within Samsung Biologics.
Samsung Biologics, based in Incheon, South Korea, boasts a comprehensive biomanufacturing capacity of 845,000 liters across its facilities in Korea and the U.S. This acquisition aims to leverage PolyPeptide's expertise in peptide-based active pharmaceutical ingredients, expanding Samsung Biologics' capabilities in a rapidly growing market. The company continues to innovate and invest in new manufacturing technologies through its ExellenS™ framework, which ensures standardized processes and speedy production.
Furthermore, the market for peptide-based pharmaceuticals is anticipated to evolve significantly, particularly in the therapeutic landscape addressing metabolic diseases. PolyPeptide has been instrumental in this field, establishing itself with a global network of GMP-certified facilities, enhancing its appeal to Samsung Biologics as a robust addition to their growing portfolio.
As both companies look forward to what could be a transformative merger, the attention of the investment community will now focus on the unfolding events during the tender offer period. With the backing of large shareholders and the support of Polypeptide’s Board, Samsung Biologics is poised to redefine its position in the biotechnology industry.
For further information, the detailed offer documentation is accessible on the Samsung Biologics website, providing transparency and clarity regarding the acquisition process. Investors and interested stakeholders are encouraged to review this material closely to understand the implications of this significant strategic development fully.
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.